<DOC>
	<DOCNO>NCT01970904</DOCNO>
	<brief_summary>This study explore relationship different DEB025 dose combination RBV pharmacokinetic , pharmacodynamic ( i.e . viral load reduction ) safety profile chronic hepatitis C GT 2 3 treatment naïve patient .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics Safety DEB025 Plus Ribavirin Chronic Hepatitis C Genotype 2 3 Treatment naïve Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1 . Written informed consent must obtain assessment perform . 2 . No previous treatment Hepatitis C ( HCV ) infection ( i.e . HCV treatmentnaïve ) 3 . Chronic hepatitis C ( G2 G3 ) virus infection diagnose Exclusion criterion : 1 . Use investigational drug time enrollment , within 30 day 5 halflives medication enrollment . 2 . History hypersensitivity study drug drug similar chemical class 3 . Hepatitis B Surface Antigen ( HBsAg ) positive 4 . Human immunodeficiency virus ( HIV ) positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>DEB025</keyword>
	<keyword>Alisporivir</keyword>
	<keyword>ribavirin therapy</keyword>
	<keyword>genotype 2/3 treatment naive patient</keyword>
</DOC>